- Home
- XZO vs TNGX Comparison
XZO vs TNGX Comparison
Compare XZO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XZO | TNGX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | XZO | TNGX |
|---|---|---|
| Price | $22.54 | $8.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $27.00 | $12.50 |
| AVG Volume (30 Days) | 198.6K | ★ 2.3M |
| Earning Date | 12-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 480.31 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $210,669,000.00 | $66,501,000.00 |
| Revenue This Year | $56.84 | $52.80 |
| Revenue Next Year | $13.24 | N/A |
| P/E Ratio | $25.94 | ★ N/A |
| Revenue Growth | ★ 138.35 | 53.29 |
| 52 Week Low | $12.92 | $1.03 |
| 52 Week High | $23.75 | $11.20 |
Technical Indicators
Market Signals| Indicator | XZO | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.06 |
| Support Level | N/A | $8.30 |
| Resistance Level | N/A | $8.82 |
| Average True Range (ATR) | 0.00 | 0.54 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 0.00 | 17.70 |
Price Performance
Historical ComparisonAbout XZO Exzeo Group Inc.
Exzeo Group Inc provides turnkey insurance technology and operations solutions to insurance carriers and their agents based on a proprietary platform of purpose-built software and data analytics applications that are specifically designed for the property and casualty, or P&C, insurance ecosystem. Its Insurance-as-a-Service (IaaS) platform, which it refers to as the Exzeo Platform, currently includes nine configurable software and data analytics applications that are purpose-built to serve insurance companies and other customers in the insurance value chain. Through the Exzeo Platform, the company provides technology-based solutions and services for all operational and administrative activities and functions needed by P&C insurance carriers and their agents.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.